ReviewJournal of fungi (Basel, Switzerland)2020
Chronic Pulmonary Aspergillosis Following Nontuberculous Mycobacterial Infections: An Emerging Disease.
Review in Journal of fungi (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Management of Adult Bronchiectasis: Consensus-Based Guidelines of the German Respiratory Society.Respiration; international review of thoracic diseases · 2026Guideline
- Clinical impact of chronic pulmonary aspergillosis in patients with pulmonary nontuberculous mycobacterial disease and colonization: a multicentre prospective cohort study.Annals of medicine · 2026Article
- Clinical Characteristics and Risk Factors for Chronic Pulmonary Aspergillosis in Patients with Nontuberculous Mycobacterial Pulmonary Disease.Journal of clinical medicine · 2026Article
- Comparative performance of Filamentous Fungi 4.0 and Mass Spectrometry Identification 2.0 databases for Aspergillus spp.: identification using a simplified protein extraction method.Revista do Instituto de Medicina Tropical de Sao Paulo · 2026Article
- Chronic Pulmonary Aspergillosis Secondary Infection: A Case Report ofClinical case reports · 2025Article
- Multicentre retrospective observational study for development and validation of MAC prognostic score model.Scientific reports · 2025Observational
- Observational
- The Advance and Clinical Practice on Lung Disease Caused byInfection and drug resistance · 2025Article
- Identification of prognostic factors of chronic pulmonary aspergillosis: a retrospective cohort of 106 patients.Journal of thoracic disease · 2024Article
- Development of allergic bronchopulmonary aspergillosis in a patient with nontuberculous mycobacterial-pulmonary disease successfully treated with dupilumab: A case report and literature review.Respirology case reports · 2024Article
- Drug-drug interactions in the management of non-tuberculous mycobacterial infections.Frontiers in microbiology · 2024Review
- Improved diagnostic markers for invasive pulmonary aspergillosis in COPD patients.Frontiers in cellular and infection microbiology · 2024Article
- Clinical Impact of Chronic Pulmonary Aspergillosis in Patients with Nontuberculous Mycobacterial Pulmonary Disease and Role of Computed Tomography in the Diagnosis.Internal medicine (Tokyo, Japan) · 2023Article
- Lady Windermere syndrome with haemoptysis: suspected pulmonary aspergilloma and MAC pulmonary disease.BMJ case reports · 2023Article
- Imaging Spectrum in Chronic Pulmonary Aspergillosis.The American journal of tropical medicine and hygiene · 2023Review
- Non-Tuberculous Mycobacteria andJournal of clinical medicine · 2022Review
- The Higher Incidence of COVID-19 in Patients With Non-Tuberculous Mycobacterial Pulmonary Disease: A Single Center Experience in Korea.Journal of Korean medical science · 2022Article
- Special Issue: Chronic Pulmonary Aspergillosis.Journal of fungi (Basel, Switzerland) · 2022Article
- Cavitating pulmonary lung lesions with more than one microbiological aetiology.BMJ case reports · 2022Article
- Incidence of Chronic Pulmonary Aspergillosis in Patients with Suspected or Confirmed NTM and TB-A Population-Based Retrospective Cohort Study.Journal of fungi (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic pulmonary aspergillosis (CPA) following nontuberculous mycobacterial (NTM) lung disease is being increasingly recognized, especially in countries where tuberculosis is not endemic, with an incidence rate of 3.9-16.7%. NTM lung disease has been identified as a predictor of mortality in CPA patients. The major risk factors for NTM-associated CPA include fibrocavitary NTM lung disease, the presence of pulmonary emphysema, and high-dose corticosteroid use. The onset of CPA is 1.5-7 years following the diagnosis of NTM lung disease. The diagnosis can be made using standard criteria; however, serological diagnosis using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.